GlassScriptPhysician profile
Corazon N Chua
NPI 1780686824
$1,440.53
in general payments reported to CMS, 2019-2025
18 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $12.66 · 2021: $182 · 2022: $121 · 2023: $251 · 2024: $325 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $363.60 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $324.12 | 2019-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $182.24 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $129.47 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $69.50 | 2019-2025 | Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $67.35 | 2021-2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $56.00 | 2021-2024 | Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.43 | 2020-2025 | Caplyta |
| Tris Pharma INC | $29.87 | 2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $26.99 | 2024 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $22.94 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $22.91 | 2025 | Rexulti |
| Abbvie INC. | $19.94 | 2023 | Vraylar |
| Lundbeck LLC | $18.87 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.38 | 2025 | Cobenfy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $15.92 | 2021 | |
| Neurocrine Biosciences, INC. | $15.58 | 2021 | |
| Shire North American Group INC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corazon Chua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.